Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Prior treatment

• Presence of central nervous system (CNS) metastases; however, subjects with previously treated brain metastases may be enrolled if clinically stable.
• Any other condition deemed by the investigator to potentially compromise study outcomes or lead to premature termination, including but not limited to: Alcohol or substance abuse，Concurrent severe medical conditions (e.g., psychiatric disorders requiring active treatment)， Familial or social circumstances that may affect patient safety, compliance, or study data collection.

Other illness

• Gastrointestinal (GI) disorders that may interfere with drug administration/absorption, including but not limited to: Dysphagia or inability to swallow tablets， Malabsorption syndrome，Refractory nausea, vomiting, or diarrhea，Chronic GI diseases (e.g., Crohn's disease, ulcerative colitis)

Lab values

• Congestive heart failure with New York Heart Association (NYHA) functional class ≥II or left ventricular ejection fraction (LVEF) \<50%.

• Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.
• Patients with RAS mutation who have disease progression or intolerance after adequate standard treatment
• Eastern Cooperative Oncology Group (ECOG) performance status in 0 or 1
• Adequate organ function